Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic
Author(s): Roberts Patricia A, Eberwein Samuel M, Youmans Danielle, Amerine Lindsey B
Issue: Mar/Apr 2021 - Volume 25, Number 2
View All Articles in Issue
Page(s): 109-113
Note: Electronic version includes supplemental material.
Download in electronic PDF format for $75
Abstract: The objective of this study was to describe the response by state boards of pharmacy pertaining to personal protective equipment shortages during the early phase of the COVID-19 pandemic. All webpages of state boards of pharmacy were independently reviewed for written guidance pertaining to personal protective equipment conservation strategies in sterile compounding and deviations from United States Pharmacopeia General Chapter <797> standards; each guidance was then reviewed for referenced sources. Of 52 state pharmacy regulatory bodies, 38 (73.08%) provided guidance to modifying personal protective equipment use during sterile compounding activities to mitigate supply shortages. The references for each guidance varied, however, most referenced CriticalPoint, LLC or the United States Pharmacopeia. A few of the guidance documents from boards also permitted other deviations from United States Pharmacopeia Chapter <797> standards. Early in the pandemic, pharmacists within sterile compounding practices had to conserve personal protective equipment while mitigating contamination risk. Pharmacists looked to state boards of pharmacy for guidance. This report shows a high level of state response to the personal protective equipment shortage induced by the pandemic.
Related Keywords:
COVID-19 pandemic, coronavirus, personal protective equipment, PPE shortage, state boards of pharmacy, PPE conservation strategies, supply chain disruption, United States Pharmacopeia Chapter <797>, USP, U.S. Food and Drug Administration, regulation, sterile compounding standards, compounded sterile preparations, microbial contamination, beyond use date modification, environmental contaminant testing
Related Categories:
ENVIRONMENTAL , STERILE PREPARATIONS, UNITED STATES PHARMACOPEIA CONVENTIONS, INFECTIOUS DISEASE, PROFESSIONAL ISSUES
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic
Roberts Patricia A, Eberwein Samuel M, Youmans Danielle, Amerine Lindsey B
|
Mar/Apr 2021
Pg. 109-113
|
Pharmacies on the Frontline: Responding to the COVID-19 Pandemic
McElhiney Linda F
|
Jul/Aug 2020
Pg. 287-295
|
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
|
Jan/Feb 2020
Pg. 30-36
|
Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants
Riepl Mike
|
Jan/Feb 2023
Pg. 12-21
|
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID
Riepl Mike, Kaiser Joe
|
Jul/Aug 2023
Pg. 284-293
|
Compounding for the Treatment of COVID-19 and Long COVID, Part 5: Associated Conditions, Prophylaxis, and Effective Treatment
Riepl Mike, Kaiser Joe
|
Sep/Oct 2023
Pg. 368-380
|
Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment
Riepl Mike
|
Mar/Apr 2023
Pg. 98-107
|
Compounding for the Treatment of COVID-19 and Long COVID, Part 3: The Role of Toll-like Receptors in SARS-CoV-2 Infection and COVID Development
Riepl Mike, Kaiser Joe
|
May/Jun 2023
Pg. 192-200
|
PreScription: COVID-19 and Compounding Pharmacists
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 268
|
Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients
Nogales Luis Marcos, Jiménez Labaig Luis, Abarca Lachén Edgar, Gil Melcón María, López-Nieves Marisol
|
Sep/Oct 2020
Pg. 358-364
|
Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance
Greeson Nicole MH, Mixon William, Allan W Chris
|
Sep/Oct 2020
Pg. 371-379
|
Art of Pharmacy v. State
Standridge Rob
|
May/Jun 2022
Pg. 182-186
|
Allowing Compounding Pharmacies to Address Drug Shortages
Broughel James
|
Mar/Apr 2022
Pg. 100-109
|
Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies
Pritchett Jon, McCrory Gary, Kraemer Cheri, Jensen Brenda, Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 7-16
|
PreScription: Endemics, Epidemics, and Pandemics
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 268
|
PreScription: State or Federal Control of Pharmacy Practice
Allen Loyd V Jr
|
May/Jun 2007
Pg. 178
|
A Permanent Path for Urgent-use Compounding? APC-supported Legislation Would Allow 503As to Fill Gaps in Coverage When 503Bs Cannot
Brunner Scott
|
Jul/Aug 2021
Pg. 296-297
|
Applying Quality of Design Concepts to Pharmacy Compounding
Timko Robert J
|
Nov/Dec 2015
Pg. 453-463
|
PreScription: Compounding Pharmacy Issues for 2017
Allen Loyd V Jr
|
Jan/Feb 2017
Pg. 4
|
Microbial Air-Sampling Equipment, Part 1: Meeting United States Pharmacopeia Chapter <797> Standards
Kastango Eric S
|
May/Jun 2008
Pg. 216-229
|
Return to Top |